Research Analysts Issue Forecasts for OPKO Health, Inc.'s FY2024 Earnings (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Stock analysts at Zacks Research raised their FY2024 earnings per share estimates for OPKO Health in a research note issued on Monday, April 15th. Zacks Research analyst I. Bandyopadhyay now anticipates that the biotechnology company will post earnings per share of ($0.35) for the year, up from their previous estimate of ($0.36). The consensus estimate for OPKO Health's current full-year earnings is ($0.33) per share. Zacks Research also issued estimates for OPKO Health's Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, Q1 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.12) EPS.

A number of other research analysts have also recently commented on OPK. Barrington Research restated an "outperform" rating and set a $1.50 price target on shares of OPKO Health in a research note on Monday, April 1st. StockNews.com cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Friday, March 1st. Piper Sandler reiterated an "overweight" rating and issued a $5.00 target price on shares of OPKO Health in a research note on Monday, April 1st. Finally, HC Wainwright reiterated a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, April 3rd.

OPKO Health Price Performance

OPK traded up $0.04 during midday trading on Wednesday, reaching $1.25. 4,732,618 shares of the company's stock were exchanged, compared to its average volume of 13,992,894. The firm has a market capitalization of $871.24 million, a price-to-earnings ratio of -5.00 and a beta of 1.82. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15. OPKO Health has a one year low of $0.85 and a one year high of $2.24. The business has a 50-day simple moving average of $1.07 and a two-hundred day simple moving average of $1.24.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). The firm had revenue of $181.90 million during the quarter, compared to analysts' expectations of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The company's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.11) earnings per share.

Insider Buying and Selling

In related news, Director Richard M. Krasno acquired 30,000 shares of the company's stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average price of $0.99 per share, for a total transaction of $29,700.00. Following the transaction, the director now directly owns 103,333 shares of the company's stock, valued at approximately $102,299.67. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other OPKO Health news, Director Richard M. Krasno bought 30,000 shares of the stock in a transaction on Monday, January 29th. The stock was purchased at an average price of $0.99 per share, with a total value of $29,700.00. Following the acquisition, the director now owns 103,333 shares of the company's stock, valued at $102,299.67. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Phillip Md Et Al Frost bought 1,500,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were acquired at an average cost of $0.98 per share, with a total value of $1,470,000.00. Following the acquisition, the chief executive officer now directly owns 207,368,225 shares in the company, valued at approximately $203,220,860.50. The disclosure for this purchase can be found here. Insiders purchased 5,030,000 shares of company stock worth $4,810,700 in the last quarter. Insiders own 47.26% of the company's stock.

Hedge Funds Weigh In On OPKO Health

Several institutional investors and hedge funds have recently made changes to their positions in OPK. Envestnet Asset Management Inc. grew its holdings in shares of OPKO Health by 29.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 58,570 shares of the biotechnology company's stock valued at $201,000 after buying an additional 13,214 shares during the period. Cetera Advisor Networks LLC grew its holdings in shares of OPKO Health by 33.7% in the 1st quarter. Cetera Advisor Networks LLC now owns 15,156 shares of the biotechnology company's stock valued at $52,000 after buying an additional 3,820 shares during the period. MetLife Investment Management LLC grew its holdings in shares of OPKO Health by 70.6% in the 1st quarter. MetLife Investment Management LLC now owns 206,296 shares of the biotechnology company's stock valued at $710,000 after buying an additional 85,349 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of OPKO Health by 73.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 7,184,414 shares of the biotechnology company's stock valued at $24,717,000 after buying an additional 3,037,320 shares during the period. Finally, Sequoia Financial Advisors LLC grew its holdings in shares of OPKO Health by 11.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 94,071 shares of the biotechnology company's stock valued at $324,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.